StockData

Seaport Therapeutics, Inc. (SPTX) shareholders

SPTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 2, 2026
$18.17−0.95 (-4.97%)

Close on Nov 17, 2026Market cap $972.65MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
69.9%
37M of 54M shares
Institutional holders
54
54 new, 0 sold out
Net institutional buying
37M
In Q2 2026
Insider trades, 12 months
3 buys · 0 sales
Net bought $20.14M

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
PureTech Health plc
Joint filing with PureTech Health LLC (31.20%), PureTech LYT, Inc. (31.20%)
16,685,01331.20%13G (passive)Jun 30, 2026
ARCH Venture Fund XII, L.P.
Joint filing with ARCH Venture Partners XII, L.P. (11.90%), ARCH Venture Partners XII, LLC (11.90%) and 4 more
6,294,95111.90%13D (active)May 4, 2026
General Atlantic (Lux) S.a r.l.
Joint filing with General Atlantic, L.P. (11.50%), General Atlantic (SPV) GP, LLC (11.50%) and 11 more
6,101,58211.50%13D (active)May 4, 2026
Zohar Daphne5,225,4979.10%13G (passive)Jun 30, 2026
Paul Steven M3,516,7186.30%13G (passive)Jun 30, 2026
Goldman Sachs & Co. LLC
Joint filing with The Goldman Sachs Group, Inc. (5.50%)
2,791,8145.50%13G (passive)May 6, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of SPTXValueChange% of portfolio
ARCH Venture Management, LLC6,294,95111.76%$136.60MNew12.42%
General Atlantic, L.P.6,101,58211.40%$132.53MNew4.56%
Sofinnova Investments, Inc.3,564,8716.66%$77.43MNew4.00%
Goldman Sachs Group Inc2,178,6424.07%$47.32MNew0.00%
Trv Gp Vi, LLC2,061,2223.85%$44.77MNew19.27%
Canada Pension Plan Investment Board1,975,7913.69%$42.91MNew0.02%
JPMorgan Chase & Co1,815,8453.39%$40.89MNew0.00%
Foresite Capital Management VI LLC1,779,5213.32%$38.65MNew6.02%
Price T Rowe Associates Inc /Md/1,308,6042.44%$28.42MNew0.00%
FMR LLC1,185,1002.21%$25.74MNew0.00%
Bellevue Group AG1,100,0002.05%$23.89MNew0.50%
Siren, L.L.C.1,095,3162.05%$23.79MNew0.48%
Jennison Associates LLC1,079,6692.02%$23.45MNew0.01%
Ra Capital Management, L.P.700,0001.31%$15.20MNew0.13%
Vanguard Capital Management LLC599,2171.12%$13.01MNew0.00%
Woodline Partners LP586,3451.10%$12.74MNew0.04%
Braidwell LP500,0000.93%$10.86MNew0.40%
Perceptive Advisors LLC500,0000.93%$10.86MNew0.16%
Principal Financial Group Inc414,6720.77%$9.01MNew0.00%
abrdn plc310,3550.58%$6.74MNew0.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20265437M69.9%54 / 00 / 037M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

FundShares% of SPTXValue% of fundAs of
JPMorgan Small Cap Growth Fund840,9311.57%$18.27M0.70%Jun 30, 2026
PGIM Jennison Health Sciences Fund438,7540.82%$7.98M0.57%May 29, 2026
Vanguard Total Stock Market Index Fund426,3710.80%$9.26M0.00%Jun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.299,3190.56%$6.50M0.05%Jun 30, 2026
JPMorgan Small Cap Blend Fund271,4990.51%$5.90M0.35%Jun 30, 2026
Fidelity Blue Chip Growth Fund235,9000.44%$4.83M0.00%Jul 31, 2026
Fidelity Growth Company Fund224,4000.42%$4.08M0.00%May 31, 2026
SmallCap Fund181,5000.34%$3.71M0.18%Jul 31, 2026
Vanguard Extended Market Index Fund165,4360.31%$3.59M0.00%Jun 30, 2026
Multi-Manager Small Cap Equity Strategies Fund107,8800.20%$1.96M0.15%May 31, 2026
Fidelity Growth Company K6 Fund62,2960.12%$1.13M0.00%May 31, 2026
Fidelity Series Growth Company Fund55,9000.10%$1.02M0.00%May 31, 2026
Fidelity Blue Chip Growth K6 Fund48,1090.09%$984.31K0.00%Jul 31, 2026
Fidelity Series Blue Chip Growth Fund43,7000.08%$894.10K0.01%Jul 31, 2026
Blackstone Alternative Multi-Strategy Fund29,5890.06%$642.67K0.02%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Daphne ZoharChief Executive Officer, Director1,094,0012.04%Nov 13, 2026
Lana GladsteinGeneral Counsel33,5150.06%May 4, 2026
Michael Cunyuan ChenChief Scientific Officer3,3510.01%May 4, 2026
Lauren WhiteChief Financial Officer6,7020.01%May 4, 2026
Antony LoebelChief Medical Officer20,1090.04%May 4, 2026
Denice TorresDirector18,4060.03%Nov 4, 2026
Robert J. HombachDirector13,0000.02%Jun 24, 2026
General Atlantic (SP), L.P.Director, 10% owner––May 6, 2026
Gap Coinvestments Iii, LlcDirector, 10% owner––May 6, 2026
General Atlantic, L.P.Director, 10% owner––May 6, 2026
GAP Coinvestments CDA, L.P.Director, 10% owner––May 6, 2026
Gap Coinvestments Iv, LlcDirector, 10% owner––May 6, 2026
(Bermuda) L.P. GAPDirector, 10% owner––May 6, 2026
General Atlantic Genpar (Bermuda), L.P.Director, 10% owner––May 6, 2026
General Atlantic Genpar, L.P.Director, 10% owner––May 6, 2026
GAP Coinvestments V, LLCDirector, 10% owner––May 6, 2026
General Atlantic (SPV) GP, LLCDirector, 10% owner6,101,58211.40%May 6, 2026
Atlantic GenPar (Lux) SCSp GeneralDirector, 10% owner6,101,58211.40%May 6, 2026
General Atlantic Partners (Lux), SCSpDirector, 10% owner––May 6, 2026
General Atlantic Partners 100, L.P.Director, 10% owner––May 6, 2026
Atlantic (Lux) S.a r.l. GeneralDirector, 10% owner––May 6, 2026
James HealyDirector1,927,1593.60%May 4, 2026
Sharon MatesDirector––May 4, 2026
Steven M. PaulDirector863,0311.61%May 4, 2026
David E. WheadonDirector––May 4, 2026
Sandra E. PetersonDirector––May 4, 2026
Jason PittsDirector––Apr 30, 2026
Health plc PureTech10% owner13,038,49324.36%May 6, 2026
PureTech LYT, Inc.10% owner––May 6, 2026
Robert Nelsen10% owner––May 4, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Daphne Zohar
Chief Executive Officer, Director
Nov 10, 2026Gift−100,000––1,094,001
Denice Torres
Director
Nov 3, 2026Buy+5,000$19.86$99.32K5,000
Robert J. Hombach
Director
Jun 22, 2026Buy+13,000$18.14$235.82K13,000
Health plc PureTech
10% owner
May 4, 2026Conversion+12,736,014––13,038,493
Health plc PureTech
10% owner
May 4, 2026Conversion+965,255––16,685,013
Health plc PureTech
10% owner
May 4, 2026Conversion+2,681,265––15,719,758
Michael Cunyuan Chen
Chief Scientific Officer
May 4, 2026Conversion+3,351––3,351
Lana Gladstein
General Counsel
May 4, 2026Conversion+33,515––33,515
Antony Loebel
Chief Medical Officer
May 4, 2026Conversion+20,109––20,109
Lauren White
Chief Financial Officer
May 4, 2026Conversion+6,702––6,702
Steven M. Paul
Director
May 4, 2026Conversion+67,031––863,031
ARCH Venture Partners XII, L.P.
10% owner
May 4, 2026Conversion+2,513,686––2,513,686
ARCH Venture Partners XII, L.P.
10% owner
May 4, 2026Conversion+2,681,265––5,194,951
ARCH Venture Partners XII, L.P.
10% owner
May 4, 2026Buy+1,100,000$18.00$19.80M6,294,951
James Healy
Director
May 4, 2026Conversion+1,927,159––1,927,159
James Healy
Director
May 4, 2026Conversion+804,379––2,731,538
Denice Torres
Director
May 4, 2026Conversion+13,406––13,406

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
18.86%
4M shares short
Days to cover
17.4
At 0M shares a day
Change since last report
+0.4%
From 4M shares
Short volume, 20 days
77.9%
Of volume reported to FINRA

Shares sold short, last 6 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Seaport Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 58,886 shares on Sep 21, 2026 over the last 90 days.

See a number that looks wrong?